Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 1 to 10 of 613 total matches.
Fitusiran (Qfitlia) for Hemophilia A and B
The Medical Letter on Drugs and Therapeutics • Jul 07, 2025 (Issue 1732)
disorder (estimated prevalence 1:5000 live
male births) characterized by insufficient levels ...
Fitusiran (Qfitlia – Sanofi), a subcutaneously injected,
antithrombin-directed, small interfering ribonucleic
acid (siRNA), has been approved by the FDA for routine
prophylaxis to prevent or reduce the frequency of
bleeding episodes in patients ≥12 years old who have
hemophilia A with or without factor VIII inhibitors or
hemophilia B with or without factor IX inhibitors. It
is the first antithrombin-lowering therapy to become
available in the US for treatment of hemophilia.
Med Lett Drugs Ther. 2025 Jul 7;67(1732):110-1 doi:10.58347/tml.2025.1732c | Show Introduction Hide Introduction
Insect Repellents
The Medical Letter on Drugs and Therapeutics • Jul 07, 2025 (Issue 1732)
, pants, and socks and avoiding outdoor
activities during peak mosquito-biting times.1 Some
insect ...
The Centers for Disease Control and Prevention
(CDC) and the Environmental Protection Agency (EPA)
recommend using insect repellents to avoid being
bitten by mosquitoes, ticks, and other arthropods
that transmit disease-causing pathogens. Repellents
applied to exposed skin should be used in conjunction
with other preventive measures such as wearing long-sleeved
shirts, pants, and socks and avoiding outdoor
activities during peak mosquito-biting times. Some
insect repellents are listed in Table 1.
Med Lett Drugs Ther. 2025 Jul 7;67(1732):105-9 doi:10.58347/tml.2025.1732a | Show Introduction Hide Introduction
A Blood Test for Alzheimer's Disease
The Medical Letter on Drugs and Therapeutics • Jul 07, 2025 (Issue 1732)
the Lumipulse G pTau217/
β-Amyloid 1-42 Plasma Ratio (Fujirebio), a blood-based
diagnostic test, for early ...
The FDA has cleared the Lumipulse G pTau217/
β-Amyloid 1-42 Plasma Ratio (Fujirebio), a bloodbased
diagnostic test, for early detection of amyloid
plaque pathology associated with Alzheimer's
disease (AD) in adults ≥50 years old who are showing
signs and symptoms of the disease. The new assay is
the first blood test for amyloid biomarkers to become
commercially available in the US. The Lumipulse
G β-Amyloid Ratio (1-42/1-40), which measures
amyloid biomarkers in cerebrospinal fluid (CSF), was
cleared by the FDA in 2022.
Med Lett Drugs Ther. 2025 Jul 7;67(1732):109 doi:10.58347/tml.2025.1732b | Show Introduction Hide Introduction
In Brief: Dupilumab (Dupixent) for Chronic Spontaneous Urticaria
The Medical Letter on Drugs and Therapeutics • Jul 07, 2025 (Issue 1732)
phenotype.1-3
STANDARD TREATMENT ― H1-antihistamines are used
for initial treatment of chronic spontaneous ...
The subcutaneously injected interleukin (IL)-4
receptor alpha antagonist dupilumab (Dupixent –
Sanofi/Regeneron) has been approved by the FDA for
treatment of chronic spontaneous urticaria in patients
≥12 years old who remain symptomatic despite H1-antihistamine treatment. Dupilumab was approved
earlier for treatment of asthma, atopic dermatitis,
chronic rhinosinusitis with nasal polyps, eosinophilic
esophagitis, prurigo nodularis, and chronic obstructive
pulmonary disease with an eosinophilic phenotype.
Med Lett Drugs Ther. 2025 Jul 7;67(1732):111-2 doi:10.58347/tml.2025.1732d | Show Introduction Hide Introduction
In Brief: Hyperthermia with Scopolamine Patches
The Medical Letter on Drugs and Therapeutics • Jun 30, 2025 (Issue 5114)
of another
drug with anticholinergic effects or exposure to an
external heat source.1
The updated label ...
The FDA has required a new warning in the label for
the scopolamine transdermal patch (Transderm-Scōp, and generics) about a risk of serious or fatal
hyperthermia. Scopolamine, an anticholinergic drug,
is FDA-approved for prevention of nausea and
vomiting associated with motion sickness or recovery
after surgery in adults; it is often used off-label to
reduce drooling in children and adolescents with
neurologic disorders.
Med Lett Drugs Ther. 2025 Jun 30;67(5114):1 doi:10.58347/tml.2025.5114a | Show Introduction Hide Introduction
In Brief: Merilog — A NovoLog Biosimilar
The Medical Letter on Drugs and Therapeutics • Jun 23, 2025 (Issue 1731)
of an open-label trial (GEMELLI 1)
in 597 patients with type 1 or type 2 diabetes. Patients
were randomized ...
The FDA has approved Merilog (Sanofi), a biosimilar to
rapid-acting insulin aspart (NovoLog), for treatment of
patients with type 1 or type 2 diabetes. Merilog is the
first rapid-acting insulin biosimilar product to become
available in the US.
Med Lett Drugs Ther. 2025 Jun 23;67(1731):104 doi:10.58347/tml.2025.1731c | Show Introduction Hide Introduction
Sunscreens
The Medical Letter on Drugs and Therapeutics • Jun 23, 2025 (Issue 1731)
can
cause erythema, photoaging, and skin cancer.1,2
Sunscreens are widely used to reduce these risks ...
Excessive exposure to ultraviolet (UV) radiation can
cause erythema, photoaging, and skin cancer.
Sunscreens are widely used to reduce these risks, but
questions remain about their effectiveness and safety.
In 2021, the FDA proposed a rule that would require
additional safety studies for some sunscreen active
ingredients and mandate better UVA protection in
sunscreen products.
Med Lett Drugs Ther. 2025 Jun 23;67(1731):97-102 doi:10.58347/tml.2025.1731a | Show Introduction Hide Introduction
Vutrisiran (Amvuttra) for Transthyretin Amyloid Cardiomyopathy
The Medical Letter on Drugs and Therapeutics • Jun 23, 2025 (Issue 1731)
-type ATTR-CM, which
is associated with aging and commonly affects men
>60 years old.1,2 ATTR-CM ...
The FDA has approved vutrisiran (Amvuttra – Alnylam), a
subcutaneously injected small interfering RNA (siRNA),
to reduce cardiovascular hospitalizations, urgent heart
failure visits, and cardiovascular death in adults with
wild-type or variant transthyretin amyloid cardiomyopathy
(ATTR-CM). Vutrisiran is the first siRNA to be
approved in the US for this indication; it was approved
earlier for treatment of polyneuropathy associated with
hereditary transthyretin-mediated amyloidosis.
Med Lett Drugs Ther. 2025 Jun 23;67(1731):102-4 doi:10.58347/tml.2025.1731b | Show Introduction Hide Introduction
Onapgo ― An Apomorphine Subcutaneous Infusion for Parkinson's Disease
The Medical Letter on Drugs and Therapeutics • Jun 17, 2025 (Issue 5113)
). Subcutaneously
injected apomorphine (Apokyn, and generics) has
been available for intermittent use for years.1 ...
Onapgo (Supernus), a solution for continuous
subcutaneous infusion containing the dopamine
agonist apomorphine, has been approved by the FDA
for treatment of motor fluctuations in adults with
advanced Parkinson's disease (PD). Subcutaneously
injected apomorphine (Apokyn, and generics) has
been available for intermittent use for years. Vyalev, a
foscarbidopa/foslevodopa solution for subcutaneous
infusion, was approved in 2024 for the same indication.
Med Lett Drugs Ther. 2025 Jun 17;67(5113):1-2 doi:10.58347/tml.2025.5113a | Show Introduction Hide Introduction
In Brief: REMS Removal for Clozapine
The Medical Letter on Drugs and Therapeutics • Jun 09, 2025 (Issue 1730)
)
program for the second-generation antipsychotic drug
clozapine (Clozaril, and others).1
Clozapine ...
The FDA has announced that prescribers, pharmacies,
and patients are no longer required to participate in
a Risk Evaluation and Mitigation Strategy (REMS)
program for the second-generation antipsychotic drug
clozapine (Clozaril, and others).
Med Lett Drugs Ther. 2025 Jun 9;67(1730):95 doi:10.58347/tml.2025.1730e | Show Introduction Hide Introduction